Skip to main content
Figure 1 | Journal of Hematology & Oncology

Figure 1

From: Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

Figure 1

Patterns of drug induced rash. The typical rash associated with MK-2206 was a widespread, reversible, generalized, erythematous, maculopapular, non-acneiform rash (A and B). In arm 3, some patients also demonstrated an acneiform rash affecting the head, face, neck, and trunk, in addition to the maculopapular MK-2206 related rash (C).

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us